SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Quarter	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Period Ending	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021
Cash & Equivalents	8.27	20.52	10.5	29.42	3.69	5.64	8.9	9.17	17.24	14.03	56.57	2.43	7.77	13.06	15.05	8.33	16.62	22.41	33.21	10.75
Short-Term Investments	94.37	86.87	86.09	81.46	2.02	7.21	11.86	21.23	20.08	30.02	-	-	-	-	-	-	-	-	-	-
Cash & Short-Term Investments	102.63	107.39	96.59	110.88	5.71	12.85	20.76	30.4	37.33	44.06	56.57	2.43	7.77	13.06	15.05	8.33	16.62	22.41	33.21	10.75
Cash Growth (YoY)	1696.29%	735.71%	365.27%	264.73%	-84.69%	-70.83%	-63.30%	1153.39%	380.11%	237.34%	275.93%	-70.89%	-53.21%	-41.72%	-54.69%	-22.50%	62.39%	77.70%	163.33%	-
Accounts Receivable	-	-	-	-	-	-	-	-	-	-	-	-	0.36	0.76	5.56	12.94	9.61	11.79	8.01	10.21
Other Receivables	1.84	1.56	0.95	0.56	-	0.02	0.05	0.1	0.22	0.19	-	-	-	-	-	-	-	-	-	-
Receivables	1.84	1.56	0.95	0.56	-	0.02	0.05	0.1	0.22	0.19	-	-	0.36	0.76	5.56	12.94	9.61	11.79	8.01	10.21
Prepaid Expenses	3.46	3.84	3.51	1.84	3.59	3.42	2.98	2.04	2.03	2.7	2.34	0.7	0.87	1.21	1.49	0.91	1.52	1.97	2.64	0.94
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.34	-
Total Current Assets	107.94	112.78	101.05	113.28	9.31	16.3	23.79	32.54	39.58	46.95	58.91	3.13	9.01	15.03	22.1	22.18	27.75	36.17	50.19	21.91
Property, Plant & Equipment	19.58	20.17	19.4	19.44	20.4	21.37	19.92	20.75	21.79	22.63	24.68	24.84	26	27.21	28.34	29.82	30.87	31.3	30.95	29.22
Long-Term Investments	105.35	110.24	46.89	50.61	-	-	-	-	-	1.24	-	-	-	-	-	-	-	-	-	-
Long-Term Deferred Charges	-	-	0.15	-	0.26	0.26	0.26	0.26	0.24	0.24	-	-	-	-	-	-	-	-	-	-
Other Long-Term Assets	5.34	5.28	5.31	0.12	0.16	0.19	0.22	0.25	0.29	0.32	0.35	0.37	0.43	0.43	0.47	0.5	0.54	-	-	-
Total Assets	238.21	248.47	172.81	183.45	30.13	38.12	44.2	53.8	61.89	71.37	83.94	28.34	35.44	42.67	50.9	52.51	59.15	67.47	81.14	51.13

Liabilities

Fiscal Quarter	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Period Ending	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021
Accounts Payable	3.86	3.54	3.15	2.95	2.62	2.52	1.69	1.3	1.17	1.24	0.95	1.08	1.4	1.44	3.68	5.48	4.94	4.98	4.46	4.12
Accrued Expenses	7.21	5.39	6.58	6.85	7.09	6.06	5.47	6.88	5.05	5.17	6.69	5.3	5.93	8.19	9.83	10.22	9.82	11.57	11.91	4.92
Current Portion of Long-Term Debt	-	-	-	-	-	0.14	0.28	-	0.62	0.84	1.05	0.54	0.11	0.44	0.77	0.03	0.03	0.03	1.8	0.02
Current Portion of Leases	0.64	0.92	0.95	0.99	0.96	0.94	0.54	0.52	0.6	0.68	0.8	0.66	0.67	0.65	0.62	1.35	1.31	1.3	1.3	1.22
Current Income Taxes Payable	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.09	-	-
Current Unearned Revenue	-	-	-	-	-	-	-	0.11	0.11	0.38	1.32	1.63	2.89	2.94	-	-	-	-	0.1	0.1
Other Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.09	0.01	0.04	0.29	6.89	0.09
Total Current Liabilities	11.71	9.85	10.68	10.79	10.68	9.65	7.98	8.82	7.55	8.3	10.81	9.21	11.01	13.67	14.99	17.1	16.14	18.26	26.46	10.47
Long-Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0.54	0.54	0.54	-	-	-	-	0.03
Long-Term Leases	4.49	5.25	5	5.2	5.46	5.71	3.86	4	4.13	3.94	4.05	3.45	3.58	3.82	3.99	4.43	4.76	5.09	5.42	5.56
Other Long-Term Liabilities	7.23	6.12	5.64	2.38	1.98	1.35	6.39	4.08	4.09	6.31	11.77	0.42	0.6	0.24	0.32	0.36	1.14	2.87	10.72	-
Total Liabilities	23.43	21.22	21.32	18.37	18.11	16.71	18.23	16.89	15.77	18.55	26.64	13.08	15.73	18.27	19.85	21.88	22.03	26.21	42.59	16.05

Shareholders' Equity

Fiscal Quarter	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Period Ending	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021
Common Stock	0.01	0.01	0	0	0	0	0	0	0	0	0	0.01	0.01	0.01	0	0	0	0	0	0
Additional Paid-In Capital	373.48	362.75	267.72	264.55	157.03	156.41	155.79	155.14	154.1	153.49	152.86	87.98	87.34	85.14	84.45	76.14	75.56	74.92	67.67	52.65
Retained Earnings	-152.26	-129.76	-110.9	-94.03	-139.48	-129.37	-124.17	-112.77	-102.42	-95.09	-90.06	-67.21	-62.1	-55.22	-47.87	-40	-32.92	-28.14	-29.13	-17.58
Treasury Stock	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-5.52	-	-
Comprehensive Income & Other	-0.93	-0.22	0.19	0.07	-0.02	-0.11	-0.14	0.05	-0.03	-0.06	0.03	-	-	-	-	-	-	-	-	-
Total Common Equity	214.79	227.25	151.49	165.07	12.02	21.41	25.97	36.9	46.12	52.82	57.3	15.26	19.72	24.4	31.06	30.62	37.12	41.26	38.55	35.08
Shareholders' Equity	214.79	227.25	151.49	165.07	12.02	21.41	25.97	36.9	46.12	52.82	57.3	15.26	19.72	24.4	31.06	30.62	37.12	41.26	38.55	35.08
Total Liabilities & Equity	238.21	248.47	172.81	183.45	30.13	38.12	44.2	53.8	61.89	71.37	83.94	28.34	35.44	42.67	50.9	52.51	59.15	67.47	81.14	51.13

Additional Metrics

Fiscal Quarter	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Period Ending	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021
Total Debt	5.13	6.17	5.95	6.19	6.42	6.78	4.67	4.52	5.34	5.45	5.91	4.65	4.9	5.46	5.93	5.8	6.09	6.41	8.52	6.82
Net Cash (Debt)	97.5	101.22	90.64	104.69	-0.71	6.07	16.09	25.88	31.98	38.61	50.66	-2.23	2.87	7.6	9.12	2.53	10.53	16	24.69	3.93
Net Cash Growth (YoY)	-	1568.24%	463.28%	304.53%	-	-84.28%	-68.23%	-	1014.26%	408.01%	455.59%	-	-72.73%	-52.49%	-63.07%	-35.66%	217.39%	256.69%	450.61%	-
Net Cash Per Share	2.03	3.33	1.48	10.87	-0.08	0.65	1.74	3.00	4.19	5.87	9.17	-0.45	0.61	1.68	2.09	0.63	2.93	5.06	9.03	2.13
Filing Date Shares Outstanding	90.99	76.46	50.95	47.61	10.41	9.29	9.29	9.23	9.23	9.23	9.23	5.23	5.23	5.04	5.04	4.3	4.3	4.3	4.3	3.52
Total Common Shares Outstanding	83.49	75.74	47.61	47.49	9.29	9.29	9.29	9.23	9.23	9.23	9.23	5.23	5.23	5.04	5.04	4.3	4.3	4.3	4.35	3.52
Working Capital	96.23	102.93	90.37	102.48	-1.37	6.64	15.81	23.72	32.03	38.65	48.09	-6.08	-2	1.37	7.1	5.08	11.61	17.91	23.74	11.44
Book Value Per Share	2.57	3.00	3.18	3.48	1.29	2.30	2.80	4.00	5.00	5.72	6.21	2.92	3.77	4.84	6.16	7.12	8.63	9.60	8.86	9.96
Tangible Book Value	214.79	227.25	151.49	165.07	12.02	21.41	25.97	36.9	46.12	52.82	57.3	15.26	19.72	24.4	31.06	30.62	37.12	41.26	38.55	35.08
Tangible Book Value Per Share	2.57	3.00	3.18	3.48	1.29	2.30	2.80	4.00	5.00	5.72	6.21	2.92	3.77	4.84	6.16	7.12	8.63	9.60	8.86	9.96
Land	0.58	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Machinery	16	14.93	14.6	14.51	14.51	14.51	14.52	14.48	14.38	14.3	11.99	11.96	11.96	11.57	11.57	11.37	11.32	9.47	8.87	8.38
Construction In Progress	0.41	1.44	0.76	-	-	-	-	0.02	0.02	0.05	-	-	-	0.33	0.31	0.4	0.92	2.13	4.61	4.92
Leasehold Improvements	16	15.57	15.47	15.42	15.42	15.42	15.42	15.42	15.42	7.06	17.65	17.65	9.3	9.3	9.3	9.28	8.76	8.78	5.7	5.61

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 12, 2026

Data Sources Report a data error